Impact of specialty drugs on the use of other medical services

American Journal of Managed Care

Volumn 14, Issue 12, 2008, Pages 821-828

  Joyce, Geoffrey F ^a   Goldman, Dana P ^a   Karaca Mandic, Pinar ^b   Lawless, Grant D ^c  

^a RAND CORPORATION   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HEALTH CARE PLANNING; HOSPITALIZATION; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL SERVICE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; COST OF ILLNESS; DISEASE PROGRESSION; DRUG PRESCRIPTIONS; EPISODE OF CARE; FEMALE; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; IMMUNOLOGIC FACTORS; INTERNATIONAL CLASSIFICATION OF DISEASES; LONGITUDINAL STUDIES; MALE; MANAGED CARE PROGRAMS; MIDDLE AGED; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 58149091493     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Newhouse J. Medicare care costs: how much welfare loss? J Econ Perspect. 1992;6(3):3-21.
2. Arthritis Foundation. Rheumatoid arthritis. http://www.arthritis. org/disease-center.php?disease_id=31. June 30, 2007.
3. National Institute of Arthritis and Musculoskeletal and Skin Diseases. Handout on Health: Rheumatoid Arthritis. May 2004. http://www.niams.nih.gov/Health_Info/Rheumatic_Disease/default.asp. Accessed August 5, 2008.
4. Egsmose C, Lund B, Borg G, et al. Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year follow-up of a prospective double blind placebo controlled study. J Rheumatol. 1995;22(12):2208- 2213.
5. Van der Heide A, Jacobs J, Bijlsma J, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs: a randomized controlled trial. Ann Intern Med. 1996;124(8):699-707.
6. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000;343(22):1594-1602.
7. Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. J Manag Care Pharm. 2006;12(7):555-569.
8. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces the relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-1276.
9. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology. 1995;45(7):1277-1285.
10. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol. 1996;39(3):285-294.
11. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet. 1998;352(9139):1498-1504.
12. Sturm R. The myth of medical cost offset. Psychiatr Serv. 2001;52(6):738-740.
13. Yelin E, Henke C, Epstein W. The work dynamics of the person with rheumatoid arthritis. Arthritis Rheum. 1987;30(5):507-512.
14. Morrow T. Therapy optimization. A new model for managing high-cost biologics. Biotechnology Healthcare. 2006:43-59.